Health condition
Monoclonal gammopathy (MGUS)
MGUS - monoclonal gammopathy of undetermined significance - means a single clone of plasma cells is producing a detectable antibody protein without causing disease; it is common with age, usually stays harmless, and needs monitoring rather than treatment.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key facts
The essentials at a glance.
The symptoms to recognise, when to seek help, which specialist to see, and what treatment usually involves.
-
Prevalence: found in around 3% of people over 50 and more with age - usually discovered incidentally on protein tests
-
Progression risk to myeloma or related conditions averages about 1% per year - meaning most people with MGUS die WITH it, never OF it
-
Risk stratification (paraprotein size, type, and free light chain ratio) sorts monitoring intensity - low-risk MGUS may need only infrequent checks
-
Specialist: a consultant haematologist establishes baseline and risk; report new bone pain, fatigue, weight loss, infections or kidney changes between checks rather than waiting
Understanding the condition
What it is and what happens next.
What causes it, how it is diagnosed, and the treatment routes available in the UK.
What it is and how it feels
MGUS is what screening-era medicine keeps finding at the edge of disease: a clone of plasma cells producing its signature monoclonal antibody - the paraprotein detected on serum electrophoresis - without any of the organ damage that defines myeloma, discovered when protein tests are run for unrelated reasons, and increasingly common with each decade of age. The diagnosis's central fact is its arithmetic: progression to myeloma, Waldenstrom's macroglobulinaemia, amyloidosis or lymphoma runs at roughly 1% per year on average, cumulative but slow, so the overwhelming majority of people with MGUS will never develop a related disease - a truth worth internalising, since the alternative is decades of unwarranted dread over what is, for most, a benign laboratory footnote.
Diagnosis and treatment routes
Initial assessment establishes that undetermined significance genuinely applies: paraprotein quantification and typing, serum free light chains, blood count, calcium and kidney function, with imaging and marrow examination reserved for higher-risk profiles or any end-organ signal - after which risk stratification (built on paraprotein level, non-IgG type and abnormal light-chain ratio) sets the monitoring rhythm, from six-monthly initially towards annual or less for stable low-risk cases. The monitoring's purpose is catching the minority who progress at a treatable stage, aided by the patient knowing the symptoms that warrant an early call: new persistent bone pain, unexplained fatigue or anaemia, recurrent infections, weight loss, or kidney function changes. Two footnotes complete the picture: MGUS itself modestly raises clot and fracture risk (worth weaving into general health planning), and certain paraproteins occasionally cause nerve or kidney problems in their own right - phenomena a haematologist screens for at baseline, and part of why the diagnosis deserves one specialist assessment even when the plan that follows is simply watchfulness. In many parts of the UK, routine NHS referrals for this kind of problem currently take 20-45+ weeks, whereas an initial appointment with a private consultant is typically available within around two weeks.
Seeing a specialist
Who to see, and how quickly you can be seen.
The specialist for this condition is usually a consultant haematologist. Your GP can refer you on the NHS, or you can arrange a private consultation directly.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any of the emergency symptoms described above.
Frequently asked
Common questions about Monoclonal gammopathy (MGUS).
Quick, plain-English answers to what people ask us most.
-
What is monoclonal gammopathy of undetermined significance (MGUS)?
MGUS is a condition in which a single clone of plasma cells produces an abnormal protein, called a monoclonal or M-protein, detectable in the blood, without causing the symptoms or organ damage seen in multiple myeloma.
-
What causes MGUS?
The exact cause isn't known, but it becomes more common with age and reflects an early, usually stable, abnormality in plasma cell behaviour that in a small proportion of people can progress over time to myeloma or a related condition.
-
Does MGUS cause any symptoms?
By definition, MGUS doesn't cause symptoms and is usually found incidentally on blood tests done for another reason. Any symptoms like bone pain, anaemia or kidney problems suggest progression to a more active condition and need prompt reassessment.
-
Is MGUS dangerous?
MGUS itself is not dangerous, but it carries a small ongoing risk, roughly 1 percent per year, of progressing to multiple myeloma or a related blood cancer, which is why regular monitoring is recommended rather than one-off reassurance.
-
Can MGUS be cured or does it need treatment?
MGUS doesn't require treatment itself, since it's not a cancer, but it is monitored over time with periodic blood tests to detect any early signs of progression to a condition that would need treatment.
-
How is MGUS monitored?
Monitoring typically involves periodic blood tests to track the level of the abnormal protein and check for signs of anaemia, kidney impairment or bone problems, with frequency based on individual risk factors identified at diagnosis.
-
When should I see a haematologist about MGUS, and how quickly can I be seen privately?
See a haematologist if MGUS is found on blood tests, to establish baseline risk and a monitoring plan, and promptly if any new symptoms like bone pain or unexplained fatigue develop. A private haematologist can typically arrange assessment within about two weeks.